Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference

被引:0
作者
J E Castro
C E Prada
R A Aguillon
S Kitada
T Fukuda
M Motta
C Wu
F Dicker
G Sun
J Y J Wang
D A Carson
J C Reed
T J Kipps
机构
[1] John and Rebecca Moores Cancer Center,Department of Biology
[2] University of California San Diego,Department of Leukemia
[3] The Burnham Institute,undefined
[4] University of California San Diego,undefined
[5] Chronic lymphocytic leukemia Research Consortium (C.R.C),undefined
[6] MD Anderson Cancer Center,undefined
来源
Leukemia | 2006年 / 20卷
关键词
apoptosis; leukemia; oligonucleotides; CpG motifs; Bcl-2;
D O I
暂无
中图分类号
学科分类号
摘要
We compared antisense phosphorothioate oligonucleotides (PS-ODN) that target BCL-2 such as Genasense® (G3139-PS), with other PS-ODN or phosphodiester-ODN (PO-ODN) in their relative capacity to induce apoptosis of chronic lymphocytic leukemia (CLL) B cells in vitro. Surprisingly, we found that thymidine-containing PS-ODN, but not PO-ODN, induced activation and apoptosis of CLL cells independent of BCL-2 antisense sequence or CpG motifs. All tested thimidine-containing PS-ODN, irrespective of their primary sequences, reduced the expression of Bcl-2 protein and increased the levels of the proapoptotic molecules p53, Bid, Bax in CLL cells. Apoptosis induced by thymidine-containing PS-ODN was preceded by cellular activation, could be blocked by the tyrosine-kinase inhibitor imatinib mesylate (Gleevec®), and was dependent on ABL kinase. We conclude that thymidine-containing PS-ODN can activate CLL cells and induce apoptosis via a mechanism that is independent of BCL-2 gene interference or CpG motifs.
引用
收藏
页码:680 / 688
页数:8
相关论文
共 212 条
[1]  
Wagner RW(1994)Gene inhibition using antisense oligodeoxynucleotides Nature 372 333-335
[2]  
Donis-Keller H(1979)Site specific enzymatic cleavage of RNA Nucleic Acids Res 7 179-192
[3]  
Crooke ST(2004)Progress in antisense technology Annu Rev Med 55 61-95
[4]  
Stephens AC(2003)Antisense oligonucleotide therapy in cancer Curr Opin Mol Ther 5 118-122
[5]  
Rivers RP(1993)bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia Blood 82 1820-1828
[6]  
Hanada M(1999)Dysregulation of apoptosis in cancer J Clin Oncol 17 2941-2953
[7]  
Delia D(1990)Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides Cancer Res 50 6565-6570
[8]  
Aiello A(1994)Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model Oncogene 9 3049-3055
[9]  
Stadtmauer E(2002)Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment Antisense Nucleic Acid Drug Dev 12 193-213
[10]  
Reed JC(2004)Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer J Clin Oncol 22 1110-1117